World-wide recurrent seasonal influenza epidemic are mainly caused by influenza A viruses. However, these are frequently resistant to currently available antiviral medications. Scientists from the Paul-Ehrlich-Institut together with international research collaborators have identified a new target protein, which can be used to help develop novel antivirals in future. This was achieved by analysing the interactions between the influenza A virus and the infected cells in humans. Cell Host Microbe reports on these research results in its online edition of 9 December.
Between two and ten million people are infected with influenza viruses, that cause seasonal annual epidemics of disease. Influenza viruses are subdivided into influenza A, B, and C and their various subtypes. Influenza A viruses often constitute the main type of the circulating influenza viruses world-wide.
Influenza viruses undergo rapid genetic changes, therefore, influenza vaccines are adapted to the circulating seasonal influenza viruses each year. Moreover, drugs against influenza viruses, so-called antivirals, are required to treat infected individuals and are needed as a future treatment option for the occurrence of new (influenza) viruses – especially in the event of a pandemic. Meanwhile, however, a great number of influenza A viruses have become resistant to the currently available antiviral medications.
An approach to new effective antivirals against viruses is to inhibit the interaction between the virus and its host, i.e. the affected cells in the infected individual, since viruses use human cell proteins to reproduce and proliferate. A blockage of the interaction between virus proteins and cell proteins could inhibit the reproduction of the viruses, thus treating influenza successfully.
So far, the exact mechanism of interaction of influenza A virus with human cells have not been fully understood. Extensive systems-level data are available worldwide, but are seemingly discordant.
A joint collaborative research effort between four international research groups – including the group of Dr Renate König, head of the research team “Cellular Aspects of Pathogen-Host Interactions” at the Paul-Ehrlich-Institut have succeeded in generating a biochemical “map” of essential influenza A virus/host interactions. They achieved this by combining extensive genomic (relating to genes) and proteomic (relating to proteins) data analyses.
With the help of this map, the scientists identified UBR4 (ubiquitin protein ligase E3 component n-recognin 4), a protein in human cells which is responsible for “budding”, i.e. separating the viruses from the cell membrane, the exiting of the pathogen from the cell and subsequent proliferation within and outside the body. The scientists assume that UBR4 is “borrowed” by the virus to deactivate a protection mechanism in humans using its enzymatic function.
According to the scientists, this protection mechanism is as yet not known in detail. The scientists assume that it causes degradation of the viral proteins thus stopping them from being transported to the cell membrane. Based on this model, the influenza A virus thus buys itself a safe passage to the cell membrane. A novel approach to developing new antiviral drugs against the influenza A virus could be to strengthen the above mentioned protective mechanism.
“One advantage of active substances acting on cellular (human) proteins essential for the virus is the fact that the human genome does not constantly change so that active substances should also show long-term efficacy”, as Dr. König explains. Another advantage is that drugs that target cellular proteins may be effective against quite different viruses which utilize the same human protein machinery, of course, without disrupting essential cell functions. And finally, cellular proteins as target structures have the potential to be used to enhance the efficacy of vaccines.
Tripathi S, Pohl MO, Zhou Y, Rodriguez-Frandsen A,, Wang G, Stein DA, Moulton HM, DeJesus P, Che J, Mulder LC, Yángüez E, Andenmatten D, Pache L, Manicassamy B, Albrecht RA, Gonzalez MG, Nguyen Q, Brass A, Elledge S, White M, Shapira S, Hacohen N, Karlas A, Meyer TF, Shales M, Gatorano A, Johnson JR, Jang G, Johnson T, Verschueren E, Sanders D, Krogan N, Shaw M, König R#, Stertz S#, García-Sastre A#, Chanda SK# (2015):
Meta- and Orthogonal Integration of Influenza ‘OMICs’ Data Reveals UBR4 as a Critical Regulator of M2 Ion Channel Membrane Trafficking. Cell Host Microbe. 2015 18: 723-735.
# Co-senior authors
The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and immunological veterinary medicinal products. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the manifold tasks performed at the institute. The Paul-Ehrlich-Institut, with its roughly 800 members of staff, also has advisory functions nationally (federal government, federal states (Länder)), and internationally (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).
http://www.pei.de/EN/information/journalists-press/press-releases/2015/20-approa... - This press release on the PEI-Website
Dr. Susanne Stöcker | idw - Informationsdienst Wissenschaft
Transport of molecular motors into cilia
28.03.2017 | Aarhus University
Asian dust providing key nutrients for California's giant sequoias
28.03.2017 | University of California - Riverside
The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.
To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
28.03.2017 | Life Sciences
28.03.2017 | Information Technology
28.03.2017 | Physics and Astronomy